Medicare proposes covering expensive Alzheimer's drug for those in clinical trials
Aduhelm is the first treatment approved in the country to slow cognitive decline in those living with Alzheimer's. Doctors have refused to prescribe it, given the lack of data and evidence behind it.
Medicare would cover an expensive and controversial Alzheimer's drug called Aduhelm, but only for those participating in clinical trials, under a proposal announced Tuesday.
The drug is intended for Alzheimer's patients in the early stages of the disease and will be limited to Medicare recipients
